Germline testing is becoming increasingly relevant in prostate cancer (PCa) screening, prognosis, and management. A subset of patients with PCa harbor pathogenic/likely pathogenic variants (P/LPVs) in genes mediating DNA-repair processes, and these P/LPVs have implications for cancer screening, treatment, and cascade testing.
As a result, it is recommended that all men with high-risk localized and metastatic PCa undergo routine germline testing. As more PCa patients undergo germline testing, it is important that clinicians and genetics experts recognize current disparities in germline testing rates among racial/ethnic minorities in the United States. The reasons for these disparities are multiple and require similarly manifold consideration to close the germline testing gap and reduce inequities in PCa screening, management, and treatment.
Prostate cancer and prostatic diseases. 2021 Nov 13 [Epub ahead of print]
Nicole Weise, Justin Shaya, Juan Javier-Desloges, Heather H Cheng, Lisa Madlensky, Rana R McKay
University of California San Diego, San Diego, CA, USA., University of Washington, Seattle, WA, USA., University of California San Diego, San Diego, CA, USA. .
PubMed http://www.ncbi.nlm.nih.gov/pubmed/34775478